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ABSTRACT  
Objective: A new compound of salicylic acid derivative, namely 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3CBB), was synthesized to find a 
compound exhibiting higher analgesic activity and smaller ulcer irritation than acetylsalicylic acid (ASA). Therefore, this study aimed to investigate 
the pharmacokinetics of this new compound in rats, following a single dose oral administration of 3CBB (45 mg/kg BW). 
Methods: Plasma samples of 9 healthy rats were collected before and up to 3 h after its oral administration, following an 18 h fasting period. Plasma 
concentrations of 3CBB were determined using a validated HPLC-DAD assay. Pharmacokinetic parameters were determined using the compartment 
model technique. All experiments were carried out in triplicate. 
Results: The pharmacokinetic parameters of 3CBB obtained were as follows: Tmax= 28.9±1.1 min, Cmax = 0.57±0.02 µg/ml, AUCtotal = 66.3±1.0 µg 
min/ml, Kel = 0.018±0.002 min-1, and T1/2el = 39.4±3.9 min. The long elimination half-life and low Cmax
Conclusion: 3CBB demonstrated a slower onset of action and longer elimination time from the body compared to ASA. Thus this new compound is 
a potential candidate to be developed as a new drug. 
 indicated that 3CBB was extensively distributed in 
the deep and very deep tissues. This confirmed the unique and special characteristics of a highly lipophilic compound like 3CBB (log P = 3.73).  
Keywords: 2-((3-(Chloromethyl)benzoyl)oxy)benzoic acid, Pharmacokinetics, Rat, HPLC-DAD 




Acetylsalicylic acid (ASA, aspirin) has been used as a non-steroidal 
anti-inflammatory drug and antiplatelet agent for decades. After oral 
administration, ASA will be absorbed rapidly, mostly in the upper 
small intestine at the low pH. The absorption of ASA follows first-order 
kinetics with the absorption half-life lies within the range from 5 to 16 
min [1]. ASA is highly bound by plasma protein (99%). It is hydrolyzed 
primarily in the liver, yielding salicylic acid. This is subsequently 
conjugated with glycine or glucuronic acid, and the conjugate is 
excreted mostly in urine [2]. The pharmacokinetic profile of ASA in 
rats after oral administration (40 mg/kg BW) was reported, with the 
following parameters area under the plasma concentration versus time 
curve from zero to infinity (AUC 0-∞) = 152.2 µg min/ml, elimination 
half-life (T1/2) = 5.66 min, peak plasma concentration (Cmax) = 9.74 
µg/ml, and time to reach maximum drug concentration in plasma 
(Tmax) = 7 min [3]. Meanwhile, other study reported the 
pharmacokinetics of ASA in human plasma after oral administration 
(500 mg/70 kg BW), with the following parameters: AUC 0-∞ = 5.12 mg 
h/ml, T1/2 = 0.422 h, Cmax = 4.84 µg/ml, Tmax
Despite its ability to inhibit inflammation and its cardioprotective 
effect, many studies reported the harmful effect of ASA such as 
gastric irritation [5, 6]. 
 = 0.5 h [4].  
To maintain the benefit of ASA and minimize its harmful effect, we 
have modified the structure of salicylic acid, by replacing the acetyl 
group with the benzoyl group, yielding a compound known as 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid (3CBB) (fig. 1). 
 
 
Fig. 1: Chemical structure of 3CBB 
The benzoyl group is more lipophilic than the acetyl group, and 
hence increasing the ability of the molecule to penetrate the 
membrane which in turn will increase its pharmacological activity. 
In our previous study, we investigated the analgesic, toxicity and 
antiplatelet effects of 3CBB. This study demonstrated that our new 
compound is more active and less toxic than ASA [7].  
To our knowledge, until now there is no study has reported the 
pharmacokinetic parameters of 3CBB. The pharmacokinetic profile 
may give a description of the onset of action, duration of action, and 
any side effects related to the 3CBB level in the systemic circulation. 
In this paper, we investigated the blood levels of this new compound 
with validated High Performance Liquid Chromatography UV 
method–Diode Array Detector (HPLC-DAD) [8, 9]. This study aimed 
to describe the pharmacokinetic profile of 3CBB in rats following 
oral administration, as a part of its development as a new drug.  
MATERIALS AND METHODS 
Chemicals and reagents 
The material used in this study was 3CBB, which was synthesized in 
our laboratory. The purity and identification of this compound were 
determined by using TLC, IR spectroscopy, 1
Methanol of HPLC grade was obtained from Merck (Germany), 
whereas acetonitrile, phosphoric acid and potassium dihydrogen 
phosphate of pro analytical grade were purchased from E. Merck 
(Germany). Distilled and deionized water was obtained from Otsuka 
(Indonesia), and pulvis gummi arabicum was purchased from 
Brataco (Indonesia).  
H-NMR, [13]C-NMR and 
The Element Energy Dispersive Spectroscopy (EDS) [7]. 
Instrumentation 
The HPLC system employed in this study was Hitachi L-2130 (Japan), 
100 μL injector (Rheodyne 7725, USA), DAD (Hitachi L-2455, Japan), 
and LiChroCART 250-4, LiChrospher 100 RP-18 (5 μm, 4×250 mm, 
Germany) as a stationary phase. Sample analysis was conducted 
isocratically using a mixture of methanol: phosphate buffer pH 4 (4:6, 
v/v) as a mobile phase at the flow rate of 1.0 ml/min. 
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The other instruments used were pH meter (Metrohm 620, 
Switzerland), centrifuge (Zentrifugen Hettich EBA 8S, Germany), vortex 
(Thermolyne, Iowa), sonicator and degassing apparatus (Branson 1210, 
USA), filter holder and Whatman filter paper with 0.45 μm pore size 
(Millipore), analytical balance (Denver, India), and micropipette 
(Socorex, Swiss). 
Animals  
Nine healthy Wistar rats (Rattus norvegicus), weighing 200 g, aged 2-3 
mo were obtained from Pusvetma (Indonesia). Experimental animals 
were housed in a temperature-controlled room (20-24 °C) with a 12 h 
light/dark cycle. They were allowed to consume food and water ad 
libitum. All experiments performed in this study obtained the ethical 
clearance, as approved by The University of Gadjah Mada Committee on 
the Use and Care of Animals (No. 00090/04/lPPT/VII/2017), acting on 
behalf of the Indonesian Government. 
Preparation of stock and working standard solutions 
A stock standard solution of 3CBB at a concentration of 4 mg/l was 
prepared by weighing and dissolving it in methanol. A solution of 
salicylic acid at a concentration of 0.24 mg/l in methanol was used 
as an internal standard. Working standard solutions were prepared 
by diluting an appropriate volume of the stock standard solution, 
yielding 0.15–4 mg/l.  
For the accuracy and precision study, an aliquot of the stock 
standard solution was diluted with 100 μl of blank plasma to yield a 
series of concentrations of 3CBB in the range of 0.24-3.0 mg/l. Fifty 
microliters of the internal standard solution were added into the 
aliquots and the resulting working standard solutions were 
transferred into 1.5 ml tubes. Afterward, 300 μl of acetonitrile was 
added into each tube, and then they were vortexed for 10 min and 
centrifuged at 3500 rpm for 2 min. The filtrate was collected and 
evaporated to dryness under nitrogen gas. The residue was 
dissolved in 50 μl of mobile phase and was used as a sample.  
Validation study 
HPLC assay condition for bioanalytical method validation according 
to US FDA guidelines have been established [10]. The selectivity of 
this HPLC assay was tested by injecting samples, consisting of six 
blank plasma obtained from six rats. The presence of the 3CBB at a 
particular retention time was evaluated [11, 12]. 
A calibration curve was determined on each day of the 6 d validation 
period. Each HPLC run consisted of blank plasma, a zero calibrator 
(blank plasma with internal standard), and non-zero calibrators, 
comprising six working standard solutions at various concentrations 
ranging from 0.15–4 mg/l. 
The accuracy and precision (intra-day and inter-day variability) 
study were performed in triplicate during the 6 d validation period, 
employing five concentrations as quality control (QC) standard 
levels, ranging from 0.24-2.64 mg/l. The accuracy and precision of 
this HPLC assay were expressed as Relative Error (%) and Relative 
Standard Deviation (%), respectively. 
The stability of analyte in plasma during storage was performed, by 
analyzing the concentrations of this compound at three conditions, 
namely fresh-thaw after 0 h, 4 h, and freeze-thaw (24 h at-20 °C). 
This study was performed in triplicate employing four QC 
concentrations (0.25, 0.5, 3, 4 mg/l) that were freshly prepared.  
Pharmacokinetic study 
Prior to treatment, rats have fasted for 18 h. The rats were 
anesthetized with ketamine intraperitoneal (100 mg/kg BW) [13]. 
After 10 min, animals were treated orally with 3CBB suspended in 1 
ml 3% pulvis gummi arabicum, with a dose of 45 mg/kg BW. Blood 
samples were withdrawn from vena caudalis and collected into 
heparinized tubes, prior to dosing (time 0) and at pre-determined 
time intervals as follows 5, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90, 
120, and 180 min. The collected blood sample was immediately 
centrifuged at 10,000 rpm for 10 min to obtain plasma and then was 
stored at-20 °C prior to analysis. Plasma concentrations were 
determined using a validated HPLC assay. Pharmacokinetic 
parameters were determined using a compartment model 
technique. All experiments were carried out in triplicate. 
RESULTS AND DISCUSSION 
Optimization of HPLC condition 
HPLC analytical method was performed isocratically using a mixture 
of methanol: phosphate buffer pH 4 (4:6, v/v) as a mobile phase at 
the flow rate of 1.0 ml/min. This was selected as the best HPLC assay 
condition, as it gave the best peak shape and resolution of peaks 
associated with salicylic acid and 3 CBB in plasma. A typical HPLC 
chromatogram demonstrating the peaks associated with blank 
plasma, 3CBB, and internal standard is shown in fig. 2. No 
interference among peaks was observed, indicating the selectivity of 
this HPLC assay. 
A calibration curve was obtained using six concentrations covering 
the linear range, in which each concentration was analyzed in six 
replicates. It was found that peaks associated with zero calibrators 
(blank plasma with endogenous substance) and internal standard 
did not interfere with the peak associated with 3CBB. The selected 
linear regression equation for 3BB used in this study was y = 
251376 x-22538, demonstrating a good correlation between 
concentration (x) and peak area (y) rcalculated = 0.99638>rtable = 
0.8114). In addition, Fcalculated = 0.145<Ftable
 
 = 4.14, indicating an 
insignificant difference between the calibration curves generated on 
each day of the 6 d validation period. 
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Fig. 2: Typical chromatogram profiles of: (a) Blank plasma, (b) Internal standard and 3CBB in plasma, (c) 3CBB in plasma. Notes: mobile 
phase was methanol: phosphate buffer pH 4 (4:6, v/v) with the flow rate of 1 ml/min; stationary phase/column was LiChrospher 100 RP-
18 (5 μm, 4 × 250 mm, Germany); detector was Diode Array Detector (DAD, Hitachi L-2455, Japan) at a wavelength of 231 nm; retention 
times were 4.52 min for internal standard and 6.6 min for 3CBB 
 
The LOQ (Limit of Quantitation) and LOD (Limit of Detection) values 
were found to be 0.1410 mg/l and 0.0423 mg/l, respectively. 
Therefore this method was relatively sensitive to determine 3CBB. 
The intra-day and inter-day variability of accuracy and precision 
studies of 3CBB are shown in table 1. The relative error of intra-day 
and inter-day variability were found to be 0.32–1.33 % and 0.46–
1.71 %, respectively. Meanwhile, the respective relative standard 
deviation of intra-day and inter-day variability were 0.05–0.62 % 
and 0.12–0.80 %. Thus this HPLC assay was relatively accurate and 
precise to be employed in this study. The mean recovery of 3CBB in 
rat plasma was found to be 100.94 % ± 0.35 %. 
 
Table 1: The intra-day and inter-day variability of accuracy and precision studies of 3CBB 
Nominal concentration 
(µg/ml) 
Intra-day variability Inter-day variabilityc Recoveryd e (%) (Mean ± 
RSDb) Accuracy (REa Precision (RSD, 
%) 
b Accuracy (RE, 
%) 




0.24 1.18 0.62 1.71 0.80 101.53±0.75 
0.72 0.86 0.27 1.27 0.26 101.14±0.32 
1.20 1.33 0.30 1.53 0.68 101.46±0.57 
1.68 0.44 0.17 0.58 0.14 100.53±0.16 
2.16 0.38 0.08 0.65 0.15 100.56±0.18 
2.64 0.32 0.05 0.46 0.12 100.41±0.12 
aRE: Relative Error (%) = (actual concentration–nominal concentration)/nominal concentration × 100%, bRSD: Relative Standard Deviation (%) = 
Standard Deviation/mean of actual concentration × 100%, cn = 3, dn = 18, en = 21 
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Table 2: Stability study of 3CBB in rat plasma 
Nominal  
concentration  (µg/ml) 
Fresh-thaw stability Freeze-thaw Stabilitya a
(-20 °C, 24 h) (mean±RSD
  
b) 0 h (mean±RSDb 4 h (mean±RSD) b) 
0.25 101.97±1.56 101.08±0.68 100.25±0.22 
0.5 103.01±1.25 102.04±1.62 100.82±0.88 
3 106.42±1.17 104.11±1.28 102.10±1.20 
4 106.90±1.19 105.81±1.20 103.41±1.15 
an = 3, b
 
The stability study of 3CBB in rat plasma is shown in table 2. The 
sample was found to be stable during storage at-20 °C for 24 h and 
thus it could be used for pharmacokinetic study. 
Pharmacokinetic study 
RSD: Relative Standard Deviation (%) 
The pharmacokinetic profile of 3CBB in rat plasma is shown in fig. 3. 
It exhibited a non-linear elimination phase, the plasma 
concentration of 3CBB increased slowly in the first 40 min and then 
rose and declined sharply within 40–60 min after oral 
administration. A tail-off profile was observed afterward. Previous 
studies [3, 14] reported that the pharmacokinetic profile of ASA 
increased dramatically in the first 5 min and then declined rapidly, 




Fig. 3: A typical pharmacokinetic profile of 3CBB in rat plasma following oral administration (45 mg/kg BW) 
 
The value of Tmax is inversely proportional to the value of the absorption 
rate constant (ka). If there is an increase in ka, it would cause a decrease 
in the value of Tmax and vice versa. The obtained Tmax
 
 value of 3CBB was 
28.9 ± 1.1 min (table 3), which is much longer than ASA (7 min) as 
reported previously [3]. This study revealed that our new product 
exhibited a slower onset of action than ASA. This might be associated 
with its higher lipophilic properties and the stability of this product 
which was not easily hydrolyzed to yield salicylic acid. 
Table 3: Calculated pharmacokinetic parameters of 3CBB in rat plasma after oral administration (45 mg/kg BW) 
Parameter 
 
3CBBa,d (mean±RSDe Acetylsalicylic acid )  
[4] [3]b c 
Kel (min-1 0.018±0.002 ) - - 
T1/2 el 39.4±3.9 (min) 25.32±7.93 5.66±1.27 
Tmax 28.9±1.1 (min) 30 7.0±1.6 
Cmax 0.57±0.02 (µg/ml) 4.84±1.73 9.74±1.09 
AUC0-∞ 66.3±1.0  (µg min/ml) 307.2±110.90 152.2±23.3 
a2-((3-(chloromethyl)benzoyl)oxy)benzoic acid, bPharmacokinetic study was performed in humans at a dose of 500 mg [4], cPharmacokinetic study 
was performed in Sprague Dawley rat at the dose of 40 mg/kg BW [3], dn = 9, e
 
RSD: Relative Standard Deviation (%) 
The following pharmacokinetic parameters were determined, 
including the time to reach the maximum concentration (Tmax), 
maximum concentration (Cmax), and the area under the curve of a 
plasma concentration versus time from 0 to infinity (AUC0-∞
The maximum concentration of one particular drug in the systemic 
circulation highlights the intensity of the drug. C
).  
max is correlated 
with the volume of distribution (Vd). If there is an increase in Vd 
value, the value of Cmax will decrease and vice versa. Vd is very useful 
for estimating the relative amount of drug within the central or 
peripheral compartment. A large value of Vd indicates the higher 
amount of drug accumulating in the peripheral tissue compared to 
that in the central compartment. The Cmax value of this new 
compound was found to be 0.57±0.02 μg/ml (table 3). The low Cmax 
is associated with a large volume of distribution. Thus it could be 
hypothesized that this new compound was extensively distributed in 
the deep and very deep tissues. This phenomenon is commonly 
expressed by a highly lipophilic compound. This new compound, 
3CBB, was reported to be more lipophilic (log P = 3.73) than ASA 
(log P = 1.21) as reported in our previous study [7]. 
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The AUCtotal  of 3CBB was found to be 66.3 ± 1.0 µg min/ml (table 3). 
Elimination kinetics of one particular drug can be described by the 
parameter of elimination half-life (T1/2el), the time required to reduce 
the blood drug level to half. Drugs can be cleared from the body 
through two main pathways namely kidneys and liver. Metabolism is a 
conversion process of the chemical structure of a drug in the body. In 
general, metabolism will convert the drug molecules to a more polar 
compound, that is more soluble in aqueous than fatty tissues, and 
hence it is more easily excreted through the kidneys. Metabolism 
reaction of the drug is facilitated by the presence of an enzyme, to 
yield an inactive compound. However, there are some metabolites that 
are more active and more toxic than their parent drugs. In this study 
the T1/2el
CONCLUSION  
 value obtained was 39.4 ± 3.9 min, which is much longer than 
the respective values of ASA 5,66 min in rats [3] and 25.32 min in 
humans [4]. Therefore 3CBB may require a much longer time for its 
elimination, compared to ASA. 
This new compound, 3CBB, exhibited the slower onset of action and 
longer elimination time from the body, compared to ASA. This is in 
agreement with the lipophilic properties of 3 CBB compared to ASA. 
Thus this new compound, considering its pharmacological and 
toxicological properties, is a potential candidate to be developed as 
an alternative drug to substitute ASA. 
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